
    
      This study was done in subjects with relapsing remitting MS or secondary progressive MS with
      the objective of assessing the safety and efficacy of 200 mg of ABT-874 weekly or QOW versus
      placebo. There were 3 phases to the study, 24 week double blind followed by 24 weeks of an
      active extension, followed by 48 weeks of double blind active extension. The trial was
      discontinued by Abbott in Aug 2006.
    
  